Company intelligence / Profile preview

Vectorgram

Ownership: Private
Development stage: Commercial

Overview

Vectorgram offers an AI-driven platform that enables rapid and scalable breast cancer screening using mammography, ultrasound, and MRI. The system can analyze thousands of cases in seconds with results delivered in about 3 seconds per scan. It supports both onsite and remote diagnosis with HIPAA-compliant archiving. No published clinical trial results are referenced; the product appears to be deployed for real-world use.

Therapeutic areas: Oncology
Modalities: DeviceSoftware (AI-driven medical imaging analysis)
Industry: Digital Health Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly listed as of June 2025.

Beyond the preview

Go deeper on Vectorgram.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vectorgram.

Explore the full profile